// App-Quantinova.ai

: Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Researchers

Presenter

  • Anuraag Kansal

Principal Investigators

  • Odette Reifsnider

  • Lora Todorova

  • Anna Coughlan

  • Kathleen F. Villa

Medical Centers

  • Evidera, Bethesda, MD

  • Jazz Pharmaceuticals,Oxford,United Kingdom

  • Jazz Pharmaceuticals, Palo Alto, CA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • daunorubicin + cytarabine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved